XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
0.728
+0.017 (2.45%)
At close: Mar 6, 2026, 4:00 PM EST
0.759
+0.031 (4.20%)
After-hours: Mar 6, 2026, 6:45 PM EST
XTL Biopharmaceuticals Employees
XTL Biopharmaceuticals had 10 employees as of December 31, 2024. The number of employees increased by 3 or 42.86% compared to the previous year.
Employees
10
Change
3
Growth
42.86%
Revenue / Employee
$96,800
Profits / Employee
-$630,800
Market Cap
6.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 3 | 42.86% |
| Dec 31, 2016 | 7 | 1 | 16.67% |
| Dec 31, 2015 | 6 | 1 | 20.00% |
| Dec 31, 2014 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| Processa Pharmaceuticals | 10 |
| Revelation Biosciences | 9 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Immuron | 7 |
| Creative Medical Technology Holdings | 4 |
XTLB News
- 7 days ago - XTL Biopharmaceuticals (XTLB) Faces Nasdaq Delisting Threat - GuruFocus
- 7 days ago - XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing - GlobeNewsWire
- 5 weeks ago - XTL Biopharmaceuticals Aims to Acquire Stake in NeuroNOS from Beyond Air (XAIR) - GuruFocus
- 5 weeks ago - XTL Update on Recent Developments - GlobeNewsWire
- 6 weeks ago - XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - GlobeNewsWire
- 7 weeks ago - XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - GlobeNewsWire
- 7 weeks ago - XTL Biopharmaceuticals To Acquire 85% Stake In NeuroNOS Ltd For $32.5 Mln - Nasdaq
- 7 weeks ago - Beyond Air (XAIR) Moves NeuroNOS to XTL Biopharmaceuticals Through Acquisition Deal - GuruFocus